Role of the EpCAM (CD326) in prostate cancer metastasis and progression

Cancer and Metastasis Reviews

Volumn 31, Issue 3-4, 2012, Pages 779-791

  Ni, Jie ^a,b   Cozzi, Paul J ^a,b   Duan, Wei ^c   Shigdar, Sarah ^c   Graham, Peter H ^a,b   John, Kearsley H ^a,b   Li, Yong ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

Author keywords

Circulating tumour cells; EpCAM; Immunotherapy; Prognosis; Prostate cancer; Targeted cancer therapy

Indexed keywords

ADECATUMUMAB; ALPHA CATENIN; ANTINEOPLASTIC AGENT; APTAMER; BETA CATENIN; CATUMAXOMAB; EPITHELIAL CELL ADHESION MOLECULE; F ACTIN; OKT 3; SMALL INTERFERING RNA; WNT PROTEIN;

ADVANCED CANCER; BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CIRCULATING TUMOR CELL; COLON CANCER; DIGESTIVE SYSTEM CANCER; GLEASON SCORE; HUMAN; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MALIGNANT ASCITES; METASTASIS; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, NEOPLASM; CELL ADHESION; CELL ADHESION MOLECULES; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867997910     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-012-9389-1     Document Type: Review

References (105)

1. Beltran, H.; Beer, T. M.; Carducci, M. A.; de Bono, J.; Gleave, M.; Hussain, M.; et al. (2011). New therapies for castration-resistant prostate cancer: efficacy and safety. European Urology, 60, 279-290.
2. Logothetis, C. J. (2002). Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology (Williston Park, N.Y.), 16(6 Suppl 6), 63-72.
3. Petrylak, D. P.; Tangen, C. M.; Hussain, M. H.; Lara, P. N.; Jr.; Jones, J. A.; Taplin, M. E.; et al. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England Journal of Medicine, 351(15), 1513-1520.
4. Tannock, I. F.; de Wit, R.; Berry, W. R.; Horti, J.; Pluzanska, A.; Chi, K. N.; et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England Journal of Medicine, 351, 1502-1512.
5. Calabro, F.; & Sternberg, C. N. (2007). Current indications for chemotherapy in prostate cancer patients. European Urology, 51, 17-26.
6. Petrylak, D. P. (2005). Future directions in the treatment of androgen-independent prostate cancer. Urology, 65(6 Suppl), 8-12.
7. Higano, C. S.; & Crawford, E. D. (2011). New and emerging agents for the treatment of castration-resistant prostate cancer. Urologic Oncology, 29(6 Suppl), S1-S8.
8. Caffo, O.; Pappagallo, G.; Brugnara, S.; Caldara, A.; di Pasquale, M. C.; Ferro, A.; et al. (2012). Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors. Urology, 79, 644-649.
9. Hao, J. L.; Cozzi, P. J.; Khatri, A.; Power, C. A.; & Li, Y. (2010). CD147/EMMPRIN and CD44 are potential therapeutic target for metastatic prostate cancer. Current Cancer Drug Targets, 10, 287-306.
10. Li, Y.; Cozzi, P. J.; & Russell, P. J. (2010). Promising tumor-associated antigens for future prostate cancer therapy. Medicinal Research Reviews, 30, 67-101.
11. Li, Y.; & Cozzi, P. J. (2010). Angiogenesis as a strategic target for prostate cancer therapy. Medicinal Research Reviews, 30, 23-66.
12. Mukherji, D.; Pezaro, C. J.; & De-Bono, J. S. (2012). MDV3100 for the treatment of prostate cancer. Expert Opinion on Investigational Drugs, 21, 227-233.
13. Villanueva, C.; Bazan, F.; Kim, S.; Demarchi, M.; Chaigneau, L.; Thiery-Vuillemin, A.; et al. (2011). Cabazitaxel: a novel microtubule inhibitor. Drugs, 71, 1251-1258.
14. Bellmunt, J.; Attard, G.; Bahl, A.; Huland, H.; Klotz, L.; Kuban, D.; et al. (2012). Advances in the management of high-risk localised and metastatic prostate cancer. British Journal of Urology International, 109(Suppl 2), 8-13.
15. Baeuerle, P. A.; & Gires, O. (2007). EpCAM (CD326) finding its role in cancer. British Journal of Cancer, 96, 417-423.
16. Patriarca, C.; Macchi, R. M.; Marschner, A. K.; & Mellstedt, H. (2012). Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treatment Reviews, 38, 68-75.
17. Went, P.; Vasei, M.; Bubendorf, L.; Terracciano, L.; Tornillo, L.; Riede, U.; et al. (2006). Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. British Journal of Cancer, 94, 128-135.
18. Armstrong, A. J.; Marengo, M. S.; Oltean, S.; Kemeny, G.; Bitting, R. L.; Turnbull, J. D.; et al. (2011). Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Molecular Cancer Research, 9, 997-1007.
19. Trzpis, M.; McLaughlin, P. M.; de Leij, L. M.; & Harmsen, M. C. (2007). Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. The American Journal of Pathology, 171, 386-395.
20. van der Gun, B. T.; Melchers, L. J.; Ruiters, M. H.; de Leij, L. F.; McLaughlin, P. M.; & Rots, M. G. (2010). EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis, 31, 1913-1921.
21. Seligson, D. B.; Pantuck, A. J.; Liu, X.; Huang, Y.; Horvath, S.; Bui, M. H.; et al. (2004). Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clinical Cancer Research, 10, 2659-2669.
22. Songun, I.; Litvinov, S. V.; van de Velde, C. J.; Pals, S. T.; Hermans, J.; & van Krieken, J. H. (2005). Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. British Journal of Cancer, 92, 1767-1772.
23. Ensinger, C.; Kremser, R.; Prommegger, R.; Spizzo, G.; & Schmid, K. W. (2006). EpCAM overexpression in thyroid carcinomas: a histopathological study of 121 cases. Journal of Immunotherapy, 29, 569-573.
24. Kimura, H.; Kato, H.; Faried, A.; Sohda, M.; Nakajima, M.; Fukai, Y.; et al. (2007). Prognostic significance of EpCAM expression in human esophageal cancer. International Journal of Oncology, 30, 171-179.
25. Hwang, E. Y.; Yu, C. H.; Cheng, S. J.; Chang, J. Y.; Chen, H. M.; & Chiang, C. P. (2009). Decreased expression of Ep-CAM protein is significantly associated with the progression and prognosis of oral squamous cell carcinomas in Taiwan. Journal of Oral Pathology & Medicine, 38, 87-93.
26. Spizzo, G.; Went, P.; Dirnhofer, S.; Obrist, P.; Simon, R.; Spichtin, H.; et al. (2004). High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Research and Treatment, 86, 207-213.
27. Varga, M.; Obrist, P.; Schneeberger, S.; Muhlmann, G.; Felgel-Farnholz, C.; Fong, D.; et al. (2004). Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clinical Cancer Research, 10, 3131-3136.
28. Brunner, A.; Prelog, M.; Verdorfer, I.; Tzankov, A.; Mikuz, G.; & Ensinger, C. (2008). EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. Journal of Clinical Pathology, 61, 307-310.
29. Fong, D.; Steurer, M.; Obrist, P.; Barbieri, V.; Margreiter, R.; Amberger, A.; et al. (2008). Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. Journal of Clinical Pathology, 61, 31-35.
30. Nubel, T.; Preobraschenski, J.; Tuncay, H.; Weiss, T.; Kuhn, S.; Ladwein, M.; et al. (2009). Claudin-7 regulates EpCAM-mediated functions in tumor progression. Molecular Cancer Research, 7, 285-299.
31. Visvader, J. E.; & Lindeman, G. J. (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Reviews. Cancer, 8, 755-768.
32. Osta, W. A.; Chen, Y.; Mikhitarian, K.; Mitas, M.; Salem, M.; Hannun, Y. A.; et al. (2004). EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Research, 64, 5818-5824.
33. Maetzel, D.; Denzel, S.; Mack, B.; Canis, M.; Went, P.; Benk, M.; et al. (2009). Nuclear signalling by tumour-associated antigen EpCAM. Nature Cell Biology, 11, 162-171.
34. Munz, M.; Baeuerle, P. A.; & Gires, O. (2009). The emerging role of EpCAM in cancer and stem cell signaling. Cancer Research, 69, 5627-5629.
35. Maaser, K.; & Borlak, J. (2008). A genome-wide expression analysis identifies a network of EpCAM-induced cell cycle regulators. British Journal of Cancer, 99, 1635-1643.
36. Gonzalez, B.; Denzel, S.; Mack, B.; Conrad, M.; & Gires, O. (2009). EpCAM is involved in maintenance of the murine embryonic stem cell phenotype. Stem Cells, 27, 1782-1791.
37. Benko, G.; Spajic, B.; Kruslin, B.; Tomas, D. (2012). Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urologic Oncology (in press).
38. Tewes, M.; Aktas, B.; Welt, A.; Mueller, S.; Hauch, S.; Kimmig, R.; et al. (2009). Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Research and Treatment, 115, 581-590.
39. Paterlini-Brechot, P.; & Benali, N. L. (2007). Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Letters, 253, 180-204.
40. Mostert, B.; Sleijfer, S.; Foekens, J. A.; & Gratama, J. W. (2009). Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treatment Reviews, 35, 463-474.
41. Kaiser, J. (2010). Medicine. Cancer's circulation problem. Science, 327, 1072-1074.
42. Miller, M. C.; Doyle, G. V.; & Terstappen, L. W. (2010). Significance of circulating tumor cells detected by the cell search system in patients with metastatic breast colorectal and prostate cancer. Journal of Oncology, 2010, 617421.
43. Morgan, T. M.; Lange, P. H.; & Vessella, R. L. (2007). Detection and characterization of circulating and disseminated prostate cancer cells. Frontiers in Bioscience, 12, 3000-3009.
44. Nagrath, S.; Sequist, L. V.; Maheswaran, S.; Bell, D. W.; Irimia, D.; Ulkus, L.; et al. (2007). Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature, 450, 1235-1239.
45. Stott, S. L.; Hsu, C. H.; Tsukrov, D. I.; Yu, M.; Miyamoto, D. T.; Waltman, B. A.; et al. (2010). Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proceedings of the National Academy of Sciences of the United States of America, 107, 18392-18397.
46. Smerage, J. B.; & Hayes, D. F. (2006). The measurement and therapeutic implications of circulating tumour cells in breast cancer. British Journal of Cancer, 94, 8-12.
47. Moreno, J. G.; Miller, M. C.; Gross, S.; Allard, W. J.; Gomella, L. G.; & Terstappen, L. W. (2005). Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology, 65, 713-718.
48. Danila, D. C.; Heller, G.; Gignac, G. A.; Gonzalez-Espinoza, R.; Anand, A.; Tanaka, E.; et al. (2007). Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clinical Cancer Research, 13, 7053-7058.
49. Garcia, J. A.; Rosenberg, J. E.; Weinberg, V.; Scott, J.; Frohlich, M.; Park, J. W.; et al. (2007). Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. British Journal of Urology International, 99, 519-524.
50. de Bono, J. S.; Scher, H. I.; Montgomery, R. B.; Parker, C.; Miller, M. C.; Tissing, H.; et al. (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical Cancer Research, 14, 6302-6309.
51. Jost, M.; Day, J. R.; Slaughter, R.; Koreckij, T. D.; Gonzales, D.; Kinnunen, M.; et al. (2010). Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood. Molecular Cancer, 9, 174.
52. Kolostova, K.; Pinterova, D.; Hoffman, R. M.; & Bobek, V. (2011). Circulating human prostate cancer cells from an orthotopic mouse model rapidly captured by immunomagnetic beads and imaged by GFP expression. Anticancer Research, 31, 1535-1539.
53. Farace, F.; Massard, C.; Vimond, N.; Drusch, F.; Jacques, N.; Billiot, F.; et al. (2011). A direct comparison of Cell Search and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. British Journal of Cancer, 105, 847-853.
54. Riethdorf, S.; Fritsche, H.; Muller, V.; Rau, T.; Schindlbeck, C.; Rack, B.; et al. (2007). Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clinical Cancer Research, 13, 920-928.
55. Wang, S.; Owens, G. E.; & Tseng, H. R. (2011). Nano fly paper technology for the capture of circulating tumor cells. Methods in Molecular Biology, 726, 141-150.
56. Hoshino, K.; Huang, Y. Y.; Lane, N.; Huebschman, M.; Uhr, J. W.; Frenkel, E. P.; et al. (2011). Microchip-based immunomagnetic detection of circulating tumor cells. Lab on a Chip, 11, 3449-3457.
57. Zheng, X.; Cheung, L. S.; Schroeder, J. A.; Jiang, L.; & Zohar, Y. (2011). A high-performance microsystem for isolating circulating tumor cells. Lab on a Chip, 11, 3269-3276.
58. Dharmasiri, U.; Njoroge, S. K.; Witek, M. A.; Adebiyi, M. G.; Kamande, J. W.; Hupert, M. L.; et al. (2011). High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system. Analytical Chemistry, 83, 2301-2309.
59. Poczatek, R. B.; Myers, R. B.; Manne, U.; Oelschlager, D. K.; Weiss, H. L.; Bostwick, D. G.; et al. (1999). Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. The Journal of Urology, 162, 1462-1466.
60. Went, P. T.; Lugli, A.; Meier, S.; Bundi, M.; Mirlacher, M.; Sauter, G.; et al. (2004). Frequent EpCam protein expression in human carcinomas. Human Pathology, 35, 122-128.
61. Zellweger, T.; Ninck, C.; Bloch, M.; Mirlacher, M.; Koivisto, P. A.; Helin, H. J.; et al. (2005). Expression patterns of potential therapeutic targets in prostate cancer. International Journal of Cancer, 113, 619-628.
62. Cunha, G. R.; Ricke, W.; Thomson, A.; Marker, P. C.; Risbridger, G.; Hayward, S. W.; et al. (2004). Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. The Journal of Steroid Biochemistry and Molecular Biology, 92, 221-236.
63. Ghosh, K.; & Ingber, D. E. (2007). Micromechanical control of cell and tissue development: implications for tissue engineering. Advanced Drug Delivery Reviews, 59, 1306-1318.
64. Chung, L. W. (2005). Better to give than receive: my exciting journey in science. Cancer Biology & Therapy, 4, 348-352.
65. Mukherjee, S.; Richardson, A. M.; Rodriguez-Canales, J.; Ylaya, K.; Erickson, H. S.; Player, A.; et al. (2009). Identification of EpCAM as a molecular target of prostate cancer stroma. The American Journal of Pathology, 175, 2277-2287.
66. Furusato, B.; Tsunoda, T.; Shaheduzzaman, S.; Nau, M. E.; Vahey, M.; Petrovics, G.; et al. (2010). Osteoblast-specific factor 2 expression in prostate cancer-associated stroma: identification through microarray technology. Urology, 75, 768-772.
67. Sung, S. Y.; & Chung, L. W. (2002). Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation, 70, 506-521.
68. Richardson, A. M.; Woodson, K.; Wang, Y.; Rodriguez-Canales, J.; Erickson, H. S.; Tangrea, M. A.; et al. (2007). Global expression analysis of prostate cancer-associated stroma and epithelia. Diagnostic Molecular Pathology, 16, 189-197.
69. Munz, M.; Kieu, C.; Mack, B.; Schmitt, B.; Zeidler, R.; & Gires, O. (2004). The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene, 23, 5748-5758.
70. Eferl, R.; & Wagner, E. F. (2003). AP-1: a double-edged sword in tumorigenesis. Nature Reviews. Cancer, 3, 859-868.
71. Sankpal, N. V.; Mayfield, J. D.; Willman, M. W.; Fleming, T. P.; & Gillanders, W. E. (2011). Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion. Breast Cancer Research, 13, R124.
72. Gostner, J. M.; Fong, D.; Wrulich, O. A.; Lehne, F.; Zitt, M.; Hermann, M.; et al. (2011). Effects of EpCAM overexpression on human breast cancer cell lines. BMC Cancer, 11, 45.
73. Carpenter, G.; & Red Brewer, M. (2009). EpCAM: another surface-to-nucleus missile. Cancer Cell, 15, 165-166.
74. Denzel, S.; Maetzel, D.; Mack, B.; Eggert, C.; Barr, G.; & Gires, O. (2009). Initial activation of EpCAM cleavage via cell-to-cell contact. BMC Cancer, 9, 402.
75. Naundorf, S.; Preithner, S.; Mayer, P.; Lippold, S.; Wolf, A.; Hanakam, F.; et al. (2002). In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. International Journal of Cancer, 100, 101-110.
76. Kurtz, J. E.; & Dufour, P. (2010). Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opinion on Biological Therapy, 10, 951-958.
77. Gires, O.; & Bauerle, P. A. (2010). EpCAM as a target in cancer therapy. Journal of Clinical Oncology, 28(15), e239-240. author reply e241-e232.
78. Bellati, F.; Napoletano, C.; Gasparri, M. L.; Visconti, V.; Zizzari, I. G.; Ruscito, I.; et al. (2011). Monoclonal antibodies in gynecological cancer: a critical point of view. Clinical & Developmental Immunology, 2011, 890758.
79. Groth, A.; Salnikov, A. V.; Ottinger, S.; Gladkich, J.; Liu, L.; Kallifatidis, G.; et al. (2012). New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody for tumor targeting. Clinical Cancer Research, 18, 1028-1038.
80. Oberneder, R.; Weckermann, D.; Ebner, B.; Quadt, C.; Kirchinger, P.; Raum, T.; et al. (2006). A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. European Journal of Cancer, 42, 2530-2538.
81. Suzuki, K.; Nakamura, K.; Kato, K.; Hamada, H.; & Tsukamoto, T. (2007). Exploration of target molecules for prostate cancer gene therapy. The Prostate, 67, 1163-1173.
82. Moldenhauer, G.; Salnikov, A. V.; Luttgau, S.; Herr, I.; Anderl, J.; & Faulstich, H. (2012). Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. Journal of the National Cancer Institute, 104, 622-634.
83. Yamashita, T.; Ji, J.; Budhu, A.; Forgues, M.; Yang, W.; Wang, H. Y.; et al. (2009). EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology, 136, 1012-1024.
84. Terris, B.; Cavard, C.; & Perret, C. (2010). EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. Journal of Hepatology, 52, 280-281.
85. Kawashima, R.; Abei, M.; Fukuda, K.; Nakamura, K.; Murata, T.; Wakayama, M.; et al. (2011). EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus. International Journal of Cancer, 129, 1244-1253.
86. Marme, A.; Strauss, G.; Bastert, G.; Grischke, E. M.; & Moldenhauer, G. (2002). Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. International Journal of Cancer, 101, 183-189.
87. Salnikov, A. V.; Groth, A.; Apel, A.; Kallifatidis, G.; Beckermann, B. M.; Khamidjanov, A.; et al. (2009). Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma. Journal of Cellular and Molecular Medicine, 13, 4023-4033.
88. Ammons, W. S.; Bauer, R. J.; Horwitz, A. H.; Chen, Z. J.; Bautista, E.; Ruan, H. H.; et al. (2003). In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule. Neoplasia, 5, 146-154.
89. Goel, S.; Bauer, R. J.; Desai, K.; Bulgaru, A.; Iqbal, T.; Strachan, B. K.; et al. (2007). Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineere monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Annals of Oncology, 18, 1704-1707.
90. Winkler, J.; Martin-Killias, P.; Pluckthun, A.; & Zangemeister-Wittke, U. (2009). EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Molecular Cancer Therapeutics, 8, 2674-2683.
91. Seimetz, D.; Lindhofer, H.; & Bokemeyer, C. (2010). Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treatment Reviews, 36, 458-467.
92. Heiss, M. M.; Strohlein, M. A.; Jager, M.; Kimmig, R.; Burges, A.; Schoberth, A.; et al. (2005). Immunotherapy of malignant ascites with trifunctional antibodies. International Journal of Cancer, 117, 435-443.
93. Burges, A.; Wimberger, P.; Kumper, C.; Gorbounova, V.; Sommer, H.; Schmalfeldt, B.; et al. (2007). Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clinical Cancer Research, 13, 3899-3905.
94. Jager, M.; Schoberth, A.; Ruf, P.; Hess, J.; Hennig, M.; Schmalfeldt, B.; et al. (2012). Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). Cancer Research, 72, 24-32.
95. Shigdar, S.; Lin, J.; Yu, Y.; Pastuovic, M.; Wei, M.; & Duan, W. (2011). RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Science, 102, 991-998.
96. Barbas, A. S.; & White, R. R. (2009). The development and testing of aptamers for cancer. Current Opinion in Investigational Drugs, 10, 572-578.
97. Al-Hajj, M.; Wicha, M. S.; Benito-Hernandez, A.; Morrison, S. J.; & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 3983-3988.
98. Dalerba, P.; Cho, R. W.; & Clarke, M. F. (2007). Cancer stem cells: models and concepts. Annual Review of Medicine, 58, 267-284.
99. O'Brien, C. A.; Pollett, A.; Gallinger, S.; & Dick, J. E. (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 445, 106-110.
100. Li, C.; Heidt, D. G.; Dalerba, P.; Burant, C. F.; Zhang, L.; Adsay, V.; et al. (2007). Identification of pancreatic cancer stem cells. Cancer Research, 67, 1030-1037.
101. Lugli, A.; Iezzi, G.; Hostettler, I.; Muraro, M. G.; Mele, V.; Tornillo, L.; et al. (2010). Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. British Journal of Cancer, 103, 382-390.
102. Han, M. E.; Jeon, T. Y.; Hwang, S. H.; Lee, Y. S.; Kim, H. J.; Shim, H. E.; et al. (2011). Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. Cellular and Molecular Life Sciences, 68, 3589-3605.
103. Meirelles, K.; Benedict, L. A.; Dombkowski, D.; Pepin, D.; Preffer, F. I.; Teixeira, J.; et al. (2012). Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proceedings of the National Academy of Sciences of the United States of America, 109, 2358-2363.
104. - objects predict overall survival in castration-resistant prostate cancer. Annals of Oncology, 21, 1851-1857.
105. Aktas, B.; Muller, V.; Tewes, M.; Zeitz, J.; Kasimir-Bauer, S.; Loehberg, C. R.; et al. (2011). Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecologic Oncology, 122, 356-360.